Landscapes / Targets
XPO1
2 drugs act on XPO1, in 9 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs2
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Nuclear export inhibitor |
Approved | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Myelofibrosis, Diffuse Large B-cell Lymphoma and 6 more | ||||
| Open drug page | |||||
WJ01024not checked |
— |
Phase 1/2 | 31 Oct 2027Phase 1/2 trial completes | ||
| Next date | 31 Oct 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 1 of 2 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026